在英国氯氮平中央非再挑战数据库注册人群中识别临床相关粒细胞缺乏症:回顾性队列研究
该回顾性队列分析了2000年5月至2021年2月英国氯氮平中央非再挑战数据库全部3029例注册患者(283726次血液检测),按阈值标准和模式标准计算粒细胞缺乏症患病率。阈值标准判定593例(19.6%),模式标准判定348例(11.4%);全样本中两者患病率分别为0.8%和0.5%。作者认为阈值定义可能过度诊断氯氮平诱导的粒细胞缺乏症,监测方案应考虑中性粒细胞变化模式。
要点
- 阈值标准判定粒细胞缺乏症593例(19.6%),模式标准判定348例(11.4%)。
- 全样本中阈值标准和模式标准患病率分别为0.8%和0.5%。
- 70%的模式标准粒细胞缺乏症患者未经过中性粒细胞减少阶段。
核心结论
- 阈值定义的粒细胞缺乏症可能过度诊断氯氮平诱导的粒细胞缺乏症(CIA)。
- 监测方案应考虑中性粒细胞变化模式以正确识别临床相关CIA。
- 与既往研究明显不同,CIA在黑人个体中发生最少,在白人个体中发生最多。
研究设计与样本
- 回顾性队列研究,分析2000年5月至2021年2月英国氯氮平中央非再挑战数据库(CNRD)全部注册患者数据。
- 纳入标准为至少一次绝对中性粒细胞计数(ANC)<1.5×10^9/L和/或白细胞计数<3.0×10^9/L。
- 共纳入3029例患者,283726次血液检测;全样本量为75533。
主要发现
- 3029例CNRD注册患者中,阈值标准判定粒细胞缺乏症593例(19.6%),模式标准判定348例(11.4%)。
- 全样本(75533)中阈值标准粒细胞缺乏症患病率为0.8%,模式标准为0.5%。
- 阈值标准粒细胞缺乏症中位时间为32周(IQR 184),模式标准为15周(IQR 170)。
- 模式标准和阈值标准粒细胞缺乏症患病率在>48岁年龄组最高。
- 患病率白人最高(18%)、男性最高(13%),黑人最低(0.1%);70%的模式标准粒细胞缺乏症患者未经过中性粒细胞减少阶段。
关键数值与推荐
- 阈值标准粒细胞缺乏症:基于ANC<1.5×10^9/L和/或白细胞计数<3.0×10^9/L判定。
- 模式标准粒细胞缺乏症:基于中性粒细胞变化模式判定。
- 全样本中阈值标准患病率0.8%,模式标准患病率0.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clozapine is the most effective antipsychotic for treatment-resistant psychosis. However, clozapine is underutilised in part because of potential agranulocytosis. Accumulating evidence indicates that below-threshold haematological readings in isolation are not diagnostic of life-threatening clozapine-induced agranulocytosis (CIA). AIMS: To examine the prevalence and timing of CIA using different diagnostic criteria and to explore demographic differences of CIA in patients registered on the UK Central Non-Rechallenge Database (CNRD). METHOD: We analysed data of all patients registered on the UK Clozaril® Patient Monitoring Service Central Non-Rechallenge Database (at least one absolute neutrophil count (ANC) < 1.5 × 109/L and/or white blood cell count < 3.0 × 109/L) between May 2000 and February 2021. We calculated prevalence rates of agranulocytosis using threshold-based and pattern-based criteria, stratified by demographic factors (gender, age and ethnicity). Differences in epidemiology based on rechallenge status and clozapine indication were explored. The proportion of patients who recorded agranulocytosis from a normal ANC was explored. RESULTS: Of the 3029 patients registered on the CNRD with 283 726 blood measurements, 593 (19.6%) were determined to have threshold-based agranulocytosis and 348 (11.4%) pattern-based agranulocytosis. In the total sample (75 533), the prevalence of threshold-based agranulocytosis and pattern-based agranulocytosis was 0.8% and 0.5%, respectively. The median time to threshold-based agranulocytosis was 32 weeks (IQR 184) and 15 (IQR 170) weeks for pattern-based agranulocytosis. Among age groups, the prevalence of pattern-based agranulocytosis and threshold-based agranulocytosis was highest in the >48 age group. Prevalence rates were greatest for White (18%) and male individuals (13%), and lowest for Black individuals (0.1%). The proportion of people who were determined to have pattern-based agranulocytosis without passing through neutropenia was 70%. CONCLUSIONS: Threshold-based definition of agranulocytosis may over-diagnose CIA. Monitoring schemes should take into consideration neutrophil patterns to correctly identify clinically relevant CIA. In marked contrast to previous studies, CIA occurred least in Black individuals and most in White individuals.
引用
- Oloyede E, Bachmann CJ, Dzahini O, et al. Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study. Br J Psychiatry. 2024. PMID: 39149780. doi:10.1192/bjp.2024.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。